dapagliflozin + sacubitril + valsartan

dapagliflozin + sacubitril + valsartan is a fixed-dose triple combination therapy under development by Althera for the treatment of heart failure. This oral medication combines three distinct mechanisms of action to address the complex pathophysiology of heart failure: dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that promotes glucosuria and natriuresis; sacubitril, a neprilysin inhibitor that increases levels of natriuretic peptides; and valsartan, an angiotensin II type 1 (AT1) receptor blocker that inhibits the renin-angiotensin-aldosterone system. By combining these agents, the therapy aims to reduce cardiac workload, improve hemodynamic status, and provide comprehensive neurohormonal blockade, aligning with current 'four-pillar' guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF).

Other names

Dapagliflozin/Sacubitril/Valsartan 5/97/103Dapagliflozin/Sacubitril/Valsartan 5/49/51Dapagliflozin/Sacubitril/Valsartan 5mg/24mg/26mg